TRINETRA › Sectors › Healthcare
Neuland Laboratories Limited (NEULANDLAB) — share price, P/E and fundamentals
Neuland Laboratories Limited (NSE: NEULANDLAB) closed at ₹19,600.00 on 30 Oct 2026, +20.4% over one year, against a 52-week range of ₹11,500.00 – ₹24,225.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 5 Aug 2026) it reported revenue of ₹642 cr and net profit of ₹148 cr, a 23.0% net margin; revenue grew 119.2% and profit grew 1,026.0% year on year.
On four consecutive filed quarters its trailing P/E is 63.1; since 16 May 2025 its own P/E has ranged from 47.2 to 126.5 (median 67.1), and today's reading is higher than 2% of those 360 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 31.5%, ROCE 36.9%, debt-to-equity 0.10, Piotroski F-score 5 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 86% of 63 sector peers; PBT margin higher than 86% of 63 sector peers; ROE higher than 97% of 63 sector peers.
Key figures
| Last close | ₹19,600.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -10.5% / +36.1% / +20.4% |
| 52-week low – high | ₹11,500.00 – ₹24,225.00 |
| Market capitalisation | ₹25,285 cr |
| Trailing P/E | 63.1 |
| Price / book | 13.49 |
| EV / EBITDA | 32.0 |
| Earnings yield | 1.6% |
| TTM EPS | ₹310.78 |
| TTM net profit | ₹401 cr |
| Quarter revenue | ₹642 cr |
| Quarter net profit | ₹148 cr |
| Net margin | 23.0% |
| Revenue growth (YoY) | +119.2% |
| Profit growth (YoY) | +1,026.0% |
| Return on equity | 31.5% |
| ROCE | 36.9% |
| Debt / equity | 0.10 |
| Current ratio | 2.09 |
| Free cash flow | ₹-43 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹90.8 cr |
Against Healthcare peers
| Metric | NEULANDLAB | Peer median | Percentile |
|---|---|---|---|
| Net margin | 23.02 | 12.67 | 86 |
| PBT margin | 30.84 | 17.57 | 86 |
| ROE | 31.51 | 13.86 | 97 |
| ROCE | 36.91 | 16.59 | 95 |
| Debt / equity | 0.10 | 0.11 | 48 |
| Cash conversion | 0.95 | 1.25 | 28 |
| Trailing P/E | 63.07 | 43.07 | 75 |
| P/B | 13.49 | 5.88 | 85 |
Questions
What is the P/E ratio of Neuland Laboratories Limited?
Neuland Laboratories Limited's trailing P/E is 63.1, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 16 May 2025 its P/E has ranged 47.2–126.5.
What were Neuland Laboratories Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Neuland Laboratories Limited reported revenue of ₹642 cr and net profit of ₹148 cr (consolidated), filed with the exchange on 5 Aug 2026.
What is Neuland Laboratories Limited's ROE?
Return on equity is 31.5% based on the balance sheet dated 31 Mar 2026.
Does Neuland Laboratories Limited have debt?
Debt-to-equity is 0.10 on the balance sheet dated 31 Mar 2026.
What is NEULANDLAB's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, NEULANDLAB traded between ₹11,500.00 and ₹24,225.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.